Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02804568 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Safety Study in Adults With Schizophrenia
A Phase 1 study, sponsored by Alkermes.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT02804568 is a Phase 1 study that has completed, run by Alkermes. The registered enrollment target is 42 participants.
The verdict
NCT02804568, a Phase 1 study, has completed, sponsored by Alkermes.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
This study will determine the safety, tolerability, and pharmacokinetics (PK) of olanzapine and samidorphan in adults with schizophrenia following 14 consecutive days of oral administration of ALKS 3831.
Interventions
- DRUG ALKS 3831
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2016-06 |
| Est. Completion | 2016-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02804568
The ClinicalTrials.gov registry entry for NCT02804568 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alkermes, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ALKS 3831 is the first listed.
NCT02804568 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02804568 about?
NCT02804568 is a clinical study titled "A Phase 1 Safety Study in Adults With Schizophrenia". This study will determine the safety, tolerability, and pharmacokinetics (PK) of olanzapine and samidorphan in adults with schizophrenia following 14 consecutive days of oral administration of ALKS 3831.
What is the current status of trial NCT02804568?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2016-06. Estimated completion is 2016-08.
What interventions are being tested in trial NCT02804568?
The interventions under investigation include: ALKS 3831 (DRUG).
Who is sponsoring clinical trial NCT02804568?
This trial is sponsored by Alkermes, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.